{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:26:20Z","timestamp":1792841180795,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","award":["2021R1A6A1A03038899"],"award-info":[{"award-number":["2021R1A6A1A03038899"]}],"id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Korea Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["HI23C1762"],"award-info":[{"award-number":["HI23C1762"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.semarthrit.2025.152721","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T15:12:34Z","timestamp":1744211554000},"page":"152721","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Risk of major adverse cardiovascular events following targeted therapy in patients with rheumatoid arthritis: a real-world analysis stratified by cardiovascular risk"],"prefix":"10.1016","volume":"73","author":[{"given":"Seung-Hun","family":"You","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo-Kyung","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-Yeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeo-Jin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun-Young","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6691-8939","authenticated-orcid":false,"given":"Yoon-Kyoung","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.semarthrit.2025.152721_bib0001","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41584-023-00969-7","article-title":"Shared inflammatory pathways of rheumatoid arthritis and atherosclerotic cardiovascular disease","volume":"19","author":"Weber","year":"2023","journal-title":"Nat Rev Rheumatol"},{"issue":"12","key":"10.1016\/j.semarthrit.2025.152721_bib0002","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1042\/CS20180306","article-title":"Atherosclerosis and inflammation: overview and updates","volume":"132","author":"Geovanini","year":"2018","journal-title":"Clin Sci (Lond)"},{"issue":"12","key":"10.1016\/j.semarthrit.2025.152721_bib0003","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/art.24092","article-title":"Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies","volume":"59","author":"Avi\u00f1a-Zubieta","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.semarthrit.2025.152721_bib0004","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1161\/01.CIR.0000054612.26458.B2","article-title":"Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis","volume":"107","author":"Solomon","year":"2003","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.semarthrit.2025.152721_bib0005","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.semarthrit.2017.08.002","article-title":"Impact of anti-rheumatic treatment on cardiovascular risk in Asian patients with rheumatoid arthritis","volume":"47","author":"Cho","year":"2018","journal-title":"Semin Arthrit Rheum"},{"key":"10.1016\/j.semarthrit.2025.152721_bib0006","doi-asserted-by":"crossref","DOI":"10.1038\/s41584-023-00969-7","article-title":"Shared inflammatory pathways of rheumatoid arthritis and atherosclerotic cardiovascular disease","author":"Weber","year":"2023","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152721_bib0007","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1136\/annrheumdis-2014-206411","article-title":"The role of rheumatoid arthritis (RA) flare and cumulative burden of RA severity in the risk of cardiovascular disease","volume":"75","author":"Myasoedova","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.semarthrit.2025.152721_bib0008","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/acr.20371","article-title":"Systematic review and meta-analysis: anti-tumor necrosis factor \u03b1 therapy and cardiovascular events in rheumatoid arthritis","volume":"63","author":"Barnabe","year":"2011","journal-title":"Arthrit Care Res (Hoboken)"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152721_bib0009","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3899\/jrheum.200265","article-title":"The risk of cardiovascular events associated with disease-modifying antirheumatic drugs in rheumatoid arthritis","volume":"48","author":"Ozen","year":"2021","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152721_bib0010","doi-asserted-by":"crossref","first-page":"R127","DOI":"10.1186\/ar4584","article-title":"The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study","volume":"16","author":"Ljung","year":"2014","journal-title":"Arthrit Res Ther"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152721_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2024.103539","article-title":"Factors associated with incident cardiovascular disease in patients with rheumatoid arthritis: a scoping review","volume":"23","author":"Hajiesmaeili","year":"2024","journal-title":"Autoimmun Rev"},{"issue":"11","key":"10.1016\/j.semarthrit.2025.152721_bib0012","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1136\/ard-2023-224185","article-title":"Time and dose-dependent effect of systemic glucocorticoids on major adverse cardiovascular event in patients with rheumatoid arthritis: a population-based study","volume":"82","author":"So","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.semarthrit.2025.152721_bib0013","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with Tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152721_bib0014","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/ard-2022-222259","article-title":"Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance","volume":"82","author":"Charles-Schoeman","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"10.1016\/j.semarthrit.2025.152721_bib0015","doi-asserted-by":"crossref","first-page":"10","DOI":"10.31138\/mjr.171023.rof","article-title":"Risk of major adverse cardiovascular events and venous thromboembolism with JAK inhibitors versus TNF inhibitors in rheumatoid arthritis patients: a systematic review and meta-analysis","volume":"35","author":"Partalidou","year":"2024","journal-title":"Mediterr J Rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152721_bib0016","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.cgh.2023.09.033","article-title":"Risk of major adverse cardiovascular events in immune-mediated inflammatory disorders on biologics and small molecules: network Meta-analysis","volume":"22","author":"Mattay","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152721_bib0017","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1136\/annrheumdis-2021-221915","article-title":"Tofacitinib and risk of cardiovascular outcomes: results from the safety of TofAcitinib in routine care patients with Rheumatoid Arthritis (STAR-RA) study","volume":"81","author":"Khosrow-Khavar","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152721_bib0018","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/acr2.11232","article-title":"Postapproval comparative safety study of Tofacitinib and biological disease-modifying antirheumatic drugs: 5-year results from a United States-based rheumatoid arthritis registry","volume":"3","author":"Kremer","year":"2021","journal-title":"ACR open rheumatology"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152721_bib0019","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1136\/ard-2022-222824","article-title":"Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study","volume":"82","author":"Hoisnard","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.semarthrit.2025.152721_bib0020","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1136\/ard-2023-225271","article-title":"Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry","volume":"83","author":"Hern\u00e1ndez-Cruz","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.semarthrit.2025.152721_bib0021","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003489","article-title":"Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observational data from the German RABBIT register","volume":"9","author":"Meissner","year":"2023","journal-title":"RMD Open"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152721_bib0022","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/ard-2022-223762","article-title":"Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme","volume":"82","author":"Frisell","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2025.152721_bib0023","doi-asserted-by":"crossref","DOI":"10.1111\/joim.13681","article-title":"Cardiovascular risk in rheumatoid arthritis patients treated with targeted synthetic and biological disease-modifying antirheumatic drugs: a multi-centre cohort study","author":"Tong","year":"2023","journal-title":"J Intern Med"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152721_bib0024","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003885","volume":"10","author":"Sakai","year":"2024","journal-title":"RMD Open"},{"issue":"4","key":"10.1016\/j.semarthrit.2025.152721_bib0025","doi-asserted-by":"crossref","first-page":"234","DOI":"10.4078\/jrd.2023.0030","article-title":"Changes in the cholesterol profile of patients with rheumatoid arthritis treated with biologics or Janus kinase inhibitors","volume":"30","author":"Koh","year":"2023","journal-title":"J Rheum Dis"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152721_bib0026","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4078\/jrd.2021.28.3.119","article-title":"Clinical study using healthcare claims database","volume":"28","author":"Park","year":"2021","journal-title":"J Rheum Dis"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152721_bib0027","doi-asserted-by":"crossref","first-page":"146","DOI":"10.4082\/kjfm.20.0062","article-title":"Conducting and reporting a clinical research using Korean healthcare claims database","volume":"41","author":"Kim","year":"2020","journal-title":"Korea J Fam Med"},{"issue":"12","key":"10.1016\/j.semarthrit.2025.152721_bib0028","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1007\/s00296-013-2833-x","article-title":"Development of an algorithm for identifying rheumatoid arthritis in the Korean National Health Insurance claims database","volume":"33","author":"Cho","year":"2013","journal-title":"Rheumatol Int"},{"issue":"11","key":"10.1016\/j.semarthrit.2025.152721_bib0029","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152721_bib0030","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s12874-021-01440-5","article-title":"Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review","volume":"21","author":"Bosco","year":"2021","journal-title":"BMC Med Res Methodol"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152721_bib0031","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003912","article-title":"Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b\/4 randomised safety study","volume":"10","author":"Buch","year":"2024","journal-title":"RMD Open"},{"issue":"Suppl 1","key":"10.1016\/j.semarthrit.2025.152721_bib0032","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1136\/annrheumdis-2023-eular.660","article-title":"OP0219 Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with JAK-inhibitors compared to bDMARDs: data from an international collaboration of registries (the \u201cJAK-POT\u201d study)","volume":"82","author":"Aymon","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"10.1016\/j.semarthrit.2025.152721_bib0033","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1136\/annrheumdis-2023-eular.660","article-title":"OP0219 Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with Jak-inhibitors compared to bdmards: data from an international collaboration of registries (THE \u201cJAK-POT\u201d STUDY)","volume":"82","author":"Aymon","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2025.152721_bib0034","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1387585","article-title":"Comparative efficacy of five approved Janus kinase inhibitors as monotherapy and combination therapy in patients with moderate-to-severe active rheumatoid arthritis: a systematic review and network meta-analysis of randomized controlled trials","volume":"15","author":"Cai","year":"2024","journal-title":"Front Pharmacol"},{"issue":"9","key":"10.1016\/j.semarthrit.2025.152721_bib0035","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1002\/acr.25356","article-title":"Prevalence of cardiovascular and cancer risk factors among rheumatoid arthritis patients prescribed JAK inhibitors and tumor necrosis factor inhibitors: a cross-sectional study","volume":"76","author":"Janak","year":"2024","journal-title":"Arthrit Care Res (Hoboken)"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017225000927?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017225000927?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T01:58:16Z","timestamp":1751594296000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017225000927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":35,"alternative-id":["S0049017225000927"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152721","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of major adverse cardiovascular events following targeted therapy in patients with rheumatoid arthritis: a real-world analysis stratified by cardiovascular risk","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152721","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"152721"}}